September 10, 2024 10:04 PM EDTUpdated 10:40 AM

BridgeBio ends development of gene therapy for adrenal gland disorder

Kyle LaHucik

Senior Reporter

BridgeBio said Tuesday night it won’t move forward with a gene therapy for a group of genetic disorders that impair adrenal glands and cause disruptions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio ends development of gene therapy for adrenal gland disorder

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Emmet Stephenson gives $150M to City of Hope for pancreatic cancer, creating million-dollar research prize

Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Breaking down silos with a new quantitative approach to drug development

Bridge­Bio ends de­vel­op­ment of gene ther­a­py for adren­al gland dis­or­der

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BridgeBio ends development of gene therapy for adrenal gland disorder